HCW Biologics' HCW11-040 outperforms pembrolizumab in reviving exhausted T cells in preclinical studies
HCWB•HCW Biologics said HCW11-040 outperformed pembrolizumab in rejuvenating exhausted T cells against human cancer cells, with comparable immune checkpoint-blocking activity. The company will present preclinical data on Nov. 7, 2026, at the Society for Immunotherapy of Cancer meeting in Phoenix.
1. Preclinical findings
HCW Biologics said its experimental cancer treatment HCW11-040 outperformed pembrolizumab in rejuvenating exhausted T cells against human cancer cells, while showing comparable immune checkpoint-blocking activity. The company will present the data on Nov. 7, 2026, at the Society for Immunotherapy of Cancer meeting in Phoenix.
2. Mouse counterpart
HCW Biologics said HCW11-050, the mouse counterpart to HCW11-040, showed stronger activity against immunologically cold solid tumors than immune checkpoint inhibitors in preclinical models.
